FDA Psychopharmacologic Drugs Advisory Committee will meet to...

Discussion in 'Parenting News' started by totoro, May 19, 2009.

  1. totoro

    totoro Mom? What's a GFG?

    (This is from CABF)

    - discuss several new drug approvals including Seroquel for schizophrenia (children ages 13-17) and bipolar disorder (children ages 10-17); Geodon capsules for bipolar disorder (children ages 10-17); and Zyprexa for schizophrenia and bipolar in adolescents. The meeting will be open to the public and will be held at Marriott Conference Centers, UMUC Inn and Conference, Center, 3501 University Blvd. East, Adelphi, MD. The hotel telephone number is 301-985-7385.

    CABF urges you to join us in presenting oral and/or written testimony to provide a voice for our children; we anticipate that there will be many antipsychiatry, antidiagnosis, antitreatment witnesses and we need to represent an important counterbalance in stating the following.

    Bipolar disorder in children is very real;
    Children need access to safe and effective treatment;
    Families need more information about all treatment options;
    We need more research on the long term safety and efficacy studies of these medications in children.
    Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

    Written submissions may be made to the contact person on or before May 26, 2009. Oral presentations from the public will be scheduled between approximately 4 p.m. and 6 p.m. on June 9, 2009, and must be submitted before May 22, 2009. Those desiring to make formal oral presentations should click on http://www.regulations.gov/fdmspublic/component/main?main=SubmitComment&o=0900006480979277 to submit a brief statement of the general nature of the arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested. Time allotted for each presentation may be limited (expect no more than 3 minutes).

    For more information, please click on http://www.fda.gov/OHRMS/DOCKETS/98fr/E9-10451.htm

    Thank you for your help; please introduce yourself if you plan to attend the meetings!

    Best regards,

    Susan Resko
    Executive Director